Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted in Bloomberg BNA Medical Devices Law & Industry Report, in “FDA Device Priorities Include Streamlining Clinical Trials,” by Bronwyn Mixter.
Following is an excerpt:
Attorney Bradley Merrill Thompson told Bloomberg BNA Sept. 27 that “it is incredibly important that the agency continue to press forward with regulatory science, because innovations in regulatory science have the potential to both protect patients from unsafe or ineffective products, but also have the potential to speed the regulatory approval process, also to the aid of patients. Improvements in regulatory science can identify better, quicker ways to assess new technologies that will lead to shorter development times.” Thompson, counsel for the Clinical Decision Support Coalition, is also an attorney at Epstein Becker & Green PC in Washington.
